The new age of biologic treatment of the ACL is coming. In The ACL Handbook: Knee Biology, Mechanics, and Treatment, the authors cover the past and current state of ACL injuries and treatment, and then introduce and explain the key concepts for understanding the new biologic approach to ACL treatment. The use of factors to enhance graft healing are reviewed, as well as an in-depth review of the science of platelet-rich plasma and its cellular components (platelets, white cells, and plasma). Chapters on in vitro models for science as well as the advantages and disadvantages of animal models for ACL research are included, as are chapters on the new technique of bio-enhanced ACL repair. All are discussed in easily readable text aimed at anyone with an interest of what is coming next in ACL surgery.

The hallmark text for nursing faculty seeking to promote the transformative teaching of caring science, Creating a Caring Science Curriculum: A Relational Emancipatory Pedagogy for Nursing reflects the paramount scholarship of Caring Science educators. This second edition intertwines visionary thinking with blueprints, exemplars, and dynamic direction for the application of fundamental principles. It goes beyond the conventional by offering a model that serves as an emancipatory, ethical-philosophical, educational, and pedagogical learning guide for both teachers and students.Divided into five units, the text addresses the history of the caring curriculum revolution and its powerful presence within nursing. Unit I lays the foundation for a Caring Science curriculum. Unit II introduces intellectual and strategic blueprints for caring-based education, including action-oriented approaches for faculty-student relations, teaching/learning skills, pedagogical practices, critical-reflective-creative approaches to evolving human consciousness, and power relation dynamics. Unit III addresses curriculum structure and design, the evolution of a caring-based college of nursing, caring in advanced practice education, and the development of caring consciousness in nurse leaders. It also features real-world exemplars of Caring Science curricula. Unit IV includes an alternative approach to clinical and course-based evaluation, and the text concludes with an exploration of the future of the Caring Science curriculum as a way of emancipating the human spirit. Each chapter is structured to maximize engagement with reflective exercises and learning activities that encourage the integration of theory and practice into the learning process. New to This Edition: Updated chapters, case studies, and learning activities Six new chapters that provide guidance on how to create a Caring Science curriculum Exemplars from institutions that have developed Caring Science curricula Key Features: Provides a broad application of Caring Science for teachers, students, and nursing leaders Features case studies of teacher/student lived learning experiences within a caring-loving pedagogical environment Encourages the integration of theory and practice into the learning process with learning activities and reflective exercises Distills the expertise of world-renowned Caring Science scholars Purchase includes digital access for use on most mobile devices or computers

For decades now, treatment for cancer has been limited to radiation, chemotherapy, surgery, and herbal remedies--all of which offering only a small measure of hope for recovery. Now, however, there may be another option with even better results. Author Anthony J. Luksas, PhD, has dedicated over fifty years to research for not just a treatment, but a cure. His decades in the field have led him to the discovery of the ages: a road map to a cure for cancer using DNA.

Since its discovery in 1953 by Watson and Crick, the DNA double helix has been thought of as the language of God. From that point on, throughout the ensuing decades, research has decoded much of that language, giving scientists a more respectable insight into the paradox of life itself. Now, furthering that insight, Dr. Luksas has determined a means of using that language to address cancer and perhaps other diseases.

Providing a wealth of information on DNA and how it functions in the body, as well as other processes important to the replication of cancerous bodies such as cell respiration and metastasis, Dr. Luksas explains his findings with the common reader in mind.

The lymphatic system has been one of the most misunderstood systems in our bodies. Until now. Cardiothoracic surgeon Dr. Gerald M. Lemole explains why a healthy lymphatic flow aids our bodies in reducing toxins that contribute to disease and injury. In ten short chapters, Dr. Lemole demystifies the lymphatic system, describes how powerful it is and shows how to maintain a healthy lymph system to combat specific diseases and health problems - from heart disease to cognitive function to weight management. Featuring sidebars with charts and graphs that illustrate basic principles, Lymph & Longevity also includes menus, recipes and information on supplements, as well as basic yoga and meditation guides. Illuminating, informative, and practical this essential guide is timelier now than ever as we continue to work to protect ourselves and our communities against COVID-19 and other viruses.

This book continues to be the definitive reference on drug metabolism with an emphasis on new scientific and regulatory developments. It has been updated based on developments that have occurred in the last 5 years, with new chapters on large molecules disposition, stereo-selectivity in drug metabolism, drug transporters and metabolic activation of drugs. Some chapters have been prepared by new authors who have emerged as subject area experts in the decade that has passed since publication of the first edition. Key Features: Continues to be the definitive reference on drug metabolism Covers the drug transporter field, disposition of protein therapeutics and metabolic activation of drugs Includes the contributions of world-class experts in their respective fields Contains the work of editors who are recognized leaders and deep content experts in the field of drug metabolism Emphasizes new scientific and regulatory developments in the field

Fundamental Concepts for New Clinical Trialists describes the core scientific concepts of designing, data monitoring, analyzing, and reporting clinical trials as well as the practical aspects of trials not typically discussed in statistical methodology textbooks. The first section of the book provides background information about clinical trials. It defines and compares clinical trials to other types of research studies and discusses clinical trial phases, registration, the protocol document, ethical issues, product development, and regulatory processes. It also includes a special chapter outlining the valuable attributes that statisticians can develop to maximize their contributions to a clinical trial. The second section examines scientific issues faced in each progressive step of a clinical trial. It covers issues in trial design, such as randomization, blinding, control-group selection, endpoint selection, superiority versus noninferiority, and parallel group versus crossover designs; data monitoring; analyses of efficacy, safety, and benefit-risk; and the reporting/publication of clinical trial results. As clinical trials remain the gold standard research studies for evaluating the effects of a medical intervention, newcomers to the field must have a fundamental understanding of the concepts to tackle real-world issues in all stages of trials. Drawing on their experiences in academia and industry, the authors provide a foundation for understanding the fundamental concepts necessary for working in clinical trials.

Na+-K+ ATPase or Na-pump ATPase, a member of "P"-type ATPase superfamily, is characterized by association of multiple isoforms mainly of it's - and - subunits. At present four different - ( -1, -2, -3 and -4) and three - ( -1, -2, and -3) isoforms have been identified in mammalian cells and their differential expressions are tissue specific. Regulation of Na+-K+ ATPase activity is an important but a complex process, which involves short-term and long-term mechanisms. Short-term regulation of Na+-K+ ATPase is either mediated by changes in intracellular Na+ concentrations that directly affect the Na+-pump activity or by phosphorylation/dephosphorylation-mediated by some stimulants leading to changes in its expression and transport properties. On the other hand, long-term regulation of Na+-K+ ATPase is mediated by hormones, such as mineralocorticoids and thyroid hormones, which cause changes in the transcription of genes of - and - subunits leading to an increased expression in the level of Na+-pump. Several studies have revealed a relatively new type of regulation that involves the association of small, single span membrane proteins with this enzyme. These proteins belong to the FXYD family, the members of which share a common signature sequence encompassing the transmembra ne domain adjacent to the isoform(s) of - subunits of Na+-K+ ATPase. Considering the extraordinary importance of Na+-K+ ATPase in cellular function, several internationally established investigators have contributed their articles in the monograph entitled "Regulation of Membrane Na+-K+ ATPase" for inspiring young scientists and graduate students to enrich their knowledge on the enzyme, and we are sure that this book will soon be considered as a comprehensive scientific literature in the area of Na+-K+ ATPase regulation in health and disease.

Platform trials test multiple therapies in one indication, one therapy for multiple indications, or both. These novel clinical trial designs can dramatically increase the cost-effectiveness of drug development, leading to life-altering medicines for people suffering from serious illnesses, possibly at lower cost. Currently, the cost of drug development is unsustainable. Furthermore, there are particular problems in rare diseases and small biomarker defined subsets in oncology, where the required sample sizes for traditional clinical trial designs may not be feasible. The editors recruited the key innovators in this domain. The 20 articles discuss trial designs from perspectives as diverse as quantum computing, patient's rights to information, and international health. The book begins with an overview of platform trials from multiple perspectives. It then describes impacts of platform trials on the pharmaceutical industry's key stakeholders: patients, regulators, and payers. Next it provides advanced statistical methods that address multiple aspects of platform trials, before concluding with a pharmaceutical executive's perspective on platform trials. Except for the statistical methods section, only a basic qualitative knowledge of clinical trials is needed to appreciate the important concepts and novel ideas presented.

Analyzing Longitudinal Clinical Trial Data: A Practical Guide provides practical and easy to implement approaches for bringing the latest theory on analysis of longitudinal clinical trial data into routine practice.The book, with its example-oriented approach that includes numerous SAS and R code fragments, is an essential resource for statisticians and graduate students specializing in medical research. The authors provide clear descriptions of the relevant statistical theory and illustrate practical considerations for modeling longitudinal data. Topics covered include choice of endpoint and statistical test; modeling means and the correlations between repeated measurements; accounting for covariates; modeling categorical data; model verification; methods for incomplete (missing) data that includes the latest developments in sensitivity analyses, along with approaches for and issues in choosing estimands; and means for preventing missing data. Each chapter stands alone in its coverage of a topic. The concluding chapters provide detailed advice on how to integrate these independent topics into an over-arching study development process and statistical analysis plan.

With the critical role of statistics in the design, conduct, analysis and reporting of clinical trials or observational studies intended for regulatory purposes, numerous guidelines have been issued by regulatory authorities around the world focusing on statistical issues related to drug development. However, the available literature on this important topic is sporadic, and often not readily accessible to drug developers or regulatory personnel. This book provides a systematic exposition of the interplay between the two disciplines, including emerging themes pertaining to the acceleration of the development of pharmaceutical medicines to serve patients with unmet needs. Features: Regulatory and statistical interactions throughout the drug development continuum The critical role of the statistician in relation to the changing regulatory and healthcare landscapes Statistical issues that commonly arise in the course of drug development and regulatory interactions Trending topics in drug development, with emphasis on current regulatory thinking and the associated challenges and opportunities The book is designed to be accessible to readers with an intermediate knowledge of statistics, and can be a useful resource to statisticians, medical researchers, and regulatory personnel in drug development, as well as graduate students in the health sciences. The authors' decades of experience in the pharmaceutical industry and academia, and extensive regulatory experience, comes through in the many examples throughout the book.

There is an increasing need for educational resources for statisticians and investigators. Reflecting this, the goal of this book is to provide readers with a sound foundation in the statistical design, conduct, and analysis of clinical trials. Furthermore, it is intended as a guide for statisticians and investigators with minimal clinical trial experience who are interested in pursuing a career in this area. The advancement in genetic and molecular technologies have revolutionized drug development. In recent years, clinical trials have become increasingly sophisticated as they incorporate genomic studies, and efficient designs (such as basket and umbrella trials) have permeated the field. This book offers the requisite background and expert guidance for the innovative statistical design and analysis of clinical trials in oncology. Key Features: Cutting-edge topics with appropriate technical background Built around case studies which give the work a "hands-on" approach Real examples of flaws in previously reported clinical trials and how to avoid them Access to statistical code on the book's website Chapters written by internationally recognized statisticians from academia and pharmaceutical companies Carefully edited to ensure consistency in style, level, and approach Topics covered include innovating phase I and II designs, trials in immune-oncology and rare diseases, among many others

This volume illustrates the functional properties of NAbs. Authors from pioneering groups report in their chapters on the tissue homeostatic, tissue regenerating and regulatory properties of NAbs and NAbs in pooled human IgG. Scientists interested in the regulation and modulation of components of the immune system found a whole variety of NAbs to cytokines with regulatory and protective functions and NAbs that modulate, e.g., dendritic cells, regulatory T cells, B cells and granulocytes. Considering the large plasma pools and initial difficulties in preparing IVIG that does not induce adverse effects upon infusion into recipients, this volume ends with a historical chapter on how pooled human plasma was fractionated and the IgG component pretreated for a safe intravenous application.

The EuroQol Group first met in Rotterdam in May 1987 determined to develop a standardised non-disease-specific instrument for valuing health-related quality of life. The book traces the activities of the Group over the next 25 years. The instrument constructed, eventually named the EQ-5D, was translated into many languages and used in a wide range of countries and settings. The book describes how the instrument's descriptive system was determined, how translation and language issues were handled, and how valuations were provided. Recent developments, in particular a 5-level version (EQ-5D-5L), and a youth version (EQ-5D-Y) are covered. The history of the institutional and administrative framework within which the Group operated is also treated.

"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings's College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.

Multiple demographic or economic parameters contribute to the origin of emerging infections, for example: poverty, urbanization, climate change, conflicts and population migrations. All these factors are a challenge to assess the impact (present and future) of parasitic diseases on public health. The intestine is a major target of these infections; it is a nutrient-rich environment harbouring a complex and dynamic population of 100 trillion microbes: the microbiome. Most researches on the microbiome focus on bacteria, which share the gut ecosystem with a population of uni- and multi cellular eukaryotic organisms that may prey on them. Our interest focuses on the families of eukaryotic microbes inhabiting the intestine, called "intestinal eukaryome", that include fungi, protists and helminths. Knowledge on the reciprocal influence between the microbiome and the eukaryome, and on their combined impact on homeostasis and intestinal diseases is scanty and can be considered as an important emerging field. Furthermore, the factors that differentiate pathogenic eukaryotes from commensals are still unknown. This book presents an overview of the science presented and discussed in the First Eukaryome Congress held from October 16th to 18th, 2019 at the Pasteur Institute in Paris. This book covers the following topics: Phylogenetic, prevalence, and diversity of intestinal eukaryotic microbes; and their (still enigmatic) historical evolution and potential contributions to mucosal immune homeostasis. Integrative biology to study the molecular cell biology of parasite-host interactions and the multiple parameters underlining the infectious process. The exploitation of tissue engineering and microfluidics to establish three-dimensional (3D) systems that help to understand homeostasis and pathological processes in the human intestine.

This book provides a user-friendly introduction to the qualitative methods most commonly used in the mental health and psychotherapy arena. * Chapters are written by leading researchers and the editors are experienced qualitative researchers, clinical trainers, and mental health practitioners * Provides chapter-by-chapter guidance on conducting a qualitative study from across a range of approaches * Offers guidance on how to review and appraise existing qualitative literature, how to choose the most appropriate method, and how to consider ethical issues * Demonstrates how specific methods have been applied to questions in mental health research * Uses examples drawn from recent research, including research with service users, in mental health practice and in psychotherapy

Repeated Measures Design with Generalized Linear Mixed Models for Randomized Controlled Trials is the first book focused on the application of generalized linear mixed models and its related models in the statistical design and analysis of repeated measures from randomized controlled trials. The author introduces a new repeated measures design called S:T design combined with mixed models as a practical and useful framework of parallel group RCT design because of easy handling of missing data and sample size reduction. The book emphasizes practical, rather than theoretical, aspects of statistical analyses and the interpretation of results. It includes chapters in which the author describes some old-fashioned analysis designs that have been in the literature and compares the results with those obtained from the corresponding mixed models. The book will be of interest to biostatisticians, researchers, and graduate students in the medical and health sciences who are involved in clinical trials. Author Website:Data sets and programs used in the book are available at http://www.medstat.jp/downloadrepeatedcrc.html

An important factor that affects the duration, complexity and cost of a clinical trial is the endpoint used to study the treatment's efficacy. When a true endpoint is difficult to use because of such factors as long follow-up times or prohibitive cost, it is sometimes possible to use a surrogate endpoint that can be measured in a more convenient or cost-effective way. This book focuses on the use of surrogate endpoint evaluation methods in practice, using SAS and R.

It is pointed out that a cancer stem cell is a type within a tumor that possesses the capacity of self-renewal and can give rise to the heterogeneous lineages of cancer cells, which comprise the tumor. It is emphasized that a unique feature of cancer stem cells is that, although conventional chemotherapy kills most cells in a tumor, cancer stem cells remain intact. Vast applications of the following specific stem cells in disease and tissue injury are discussed: embryonic stem cells, human mesenchymal stem cells, cancer stem cells, arterial stem cells, neural stem cells, cardiac stem cells, dental stem cells, limbal stem cells, and hematopoietic stem cells. Because human embryonic stem cells possess the potential to produce unlimited quantities of any human cell type, considerable focus is placed on their therapeutic potential in this volume. These cells are used in tissue engineering, regenerative medicine, pharmacological and toxicological studies, and fundamental studies of cell differentiation. It is pointed out that the formation of embryoid bodies, which are three-dimensional aggregates of embryonic cells, is the initial step in the differentiation of these cells. Therapeutic implications of signalling pathways in cancer stem cells are pointed out. Targeting self-renewal pathways in cancer stem cells are also included. Application of mesenchymal stem cells for treating ischemic brain injury is explained. Neural stem cells proliferation into the surrounding area of the traumatic brain injury is explained.

"

This book presents an original combination of three well-known methodological approaches for nonlinear data analysis: recurrence, networks, and fuzzy logic. After basic concepts of these three approaches are introduced, this book presents recently developed methods known as fuzzy recurrence plots and fuzzy recurrence networks. Computer programs written in MATLAB, which implement the basic algorithms, are included to facilitate the understanding of the developed ideas. Several applications of these techniques to biomedical problems, ranging from cancer and neurodegenerative disease to depression, are illustrated to show the potential of fuzzy recurrence methods. This book opens a new door to theorists in complex systems science as well as specialists in medicine, biology, engineering, physics, computer science, geosciences, and social economics to address issues in experimental nonlinear signal and data processing.

Contemporary developments in the biosciences associated with new biological possibilities have generated considerable interest among the social sciences, primarily because they challenge our understanding of the relationship between the body, nature, and identity. Regenerative medicine is such a field, and has attracted major commercial, clinical, political and popular interest. It has, however, been subject to very limited social science analysis. This book explores the hype and promise associated with the field, the uneven and often failed commercial exploitation we have seen, and the political, legal and bioethical challenges that developments in the regenerative medicine field produce. It does this at a global level, including analysis of what we are seeing in the US, Europe, China and Australia. The book establishes the meaning, boundaries and likely future development we will see, and asks whether regenerative medicine heralds a new paradigm for medicine itself.

Building on its best-selling predecessors, Basic Statistics and Pharmaceutical Statistical Applications, Third Edition covers statistical topics most relevant to those in the pharmaceutical industry and pharmacy practice. It focuses on the fundamentals required to understand descriptive and inferential statistics for problem solving. Incorporating new material in virtually every chapter, this third edition now provides information on software applications to assist with evaluating data. New to the Third Edition Use of Excel (R) and Minitab (R) for performing statistical analysis Discussions of nonprobability sampling procedures, determining if data is normally distributed, evaluation of covariances, and testing for precision equivalence Expanded sections on regression analysis, chi square tests, tests for trends with ordinal data, and tests related to survival statistics Additional nonparametric procedures, including the one-sided sign test, Wilcoxon signed-ranks test, and Mood's median test With the help of flow charts and tables, the author dispels some of the anxiety associated with using basic statistical tests in the pharmacy profession and helps readers correctly interpret their results using statistical software. Through the text's worked-out examples, readers better understand how the mathematics works, the logic behind many of the equations, and the tests' outcomes.

Interval-Censored Time-to-Event Data: Methods and Applications collects the most recent techniques, models, and computational tools for interval-censored time-to-event data. Top biostatisticians from academia, biopharmaceutical industries, and government agencies discuss how these advances are impacting clinical trials and biomedical research. Divided into three parts, the book begins with an overview of interval-censored data modeling, including nonparametric estimation, survival functions, regression analysis, multivariate data analysis, competing risks analysis, and other models for interval-censored data. The next part presents interval-censored methods for current status data, Bayesian semiparametric regression analysis of interval-censored data with monotone splines, Bayesian inferential models for interval-censored data, an estimator for identifying causal effect of treatment, and consistent variance estimation for interval-censored data. In the final part, the contributors use Monte Carlo simulation to assess biases in progression-free survival analysis as well as correct bias in interval-censored time-to-event applications. They also present adaptive decision making methods to optimize the rapid treatment of stroke, explore practical issues in using weighted logrank tests, and describe how to use two R packages. A practical guide for biomedical researchers, clinicians, biostatisticians, and graduate students in biostatistics, this volume covers the latest developments in the analysis and modeling of interval-censored time-to-event data. It shows how up-to-date statistical methods are used in biopharmaceutical and public health applications.

In clinical trial practice, controversial statistical issues inevitably occur regardless of the compliance with good statistical practice and good clinical practice. But by identifying the causes of the issues and correcting them, the study objectives of clinical trials can be better achieved. Controversial Statistical Issues in Clinical Trials covers commonly encountered controversial statistical issues in clinical trials and, whenever possible, makes recommendations to resolve these problems. The book focuses on issues occurring at various stages of clinical research and development, including early-phase clinical development (such as bioavailability/bioequivalence), bench-to-bedside translational research, and late-phase clinical development. Numerous examples illustrate the impact of these issues on the evaluation of the safety and efficacy of the test treatment under investigation. The author also offers recommendations regarding possible resolutions of the problems. Written by one of the preeminent experts in the field, this book provides a useful desk reference and state-of-the art examination of problematic issues in clinical trials for scientists in the pharmaceutical industry, medical/statistical reviewers in government regulatory agencies, and researchers and students in academia.

Accurate sample size calculation ensures that clinical studies have adequate power to detect clinically meaningful effects. This results in the efficient use of resources and avoids exposing a disproportionate number of patients to experimental treatments caused by an overpowered study. Sample Size Calculations for Clustered and Longitudinal Outcomes in Clinical Research explains how to determine sample size for studies with correlated outcomes, which are widely implemented in medical, epidemiological, and behavioral studies. The book focuses on issues specific to the two types of correlated outcomes: longitudinal and clustered. For clustered studies, the authors provide sample size formulas that accommodate variable cluster sizes and within-cluster correlation. For longitudinal studies, they present sample size formulas to account for within-subject correlation among repeated measurements and various missing data patterns. For multiple levels of clustering, the level at which to perform randomization actually becomes a design parameter. The authors show how this can greatly impact trial administration, analysis, and sample size requirement. Addressing the overarching theme of sample size determination for correlated outcomes, this book provides a useful resource for biostatisticians, clinical investigators, epidemiologists, and social scientists whose research involves trials with correlated outcomes. Each chapter is self-contained so readers can explore topics relevant to their research projects without having to refer to other chapters.